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BY Dana N LeVine, DVM, DACVIM, PhD 
Assistant Professor, Small Animal Internal Medicine 
Dr. LeVine, board-certified small animal 
internist, is passionate about all things 
hematologic. She has two ongoing research 
studies that focus on immune-mediated 
blood disorders. Both studies are soliciting 
canine subjects. 
The first study investigates reasons  
for thrombosis in immune-mediated  
hemolytic anemia (IMHA). Most dogs 
that die of IMHA die due to fatal thrombi. 
Although clinicians do their best to anti- 
coagulate these patients, the ideal protocol 
remains unknown, and thrombi still occur. 
Recently, neutrophils have been shown  
to release their DNA when activated,  
forming webs of DNA called neutrophil 
extracellular traps (NETs) that capture  
bacteria. However, these NETs are also  
very procoagulant. Dr. LeVine is studying 
the role of NETs in IMHA in order to find  
a novel therapeutic target to prevent  
IMHA-associated thrombosis. To enroll  
in this study, owners must sign an  
informed consent agreeing to allow a  
10 ml (2 teaspoon) blood sample and a 
voided urine sample to be collected. Dogs 
receive a Coomb’s test, paid for by the 
study, if the diagnosis of IMHA is uncertain.
The second study, funded by the  
American Kennel Club Canine Health 
Foundation, focuses on immune  
thrombocytopenia (ITP). ITP is the most 
common acquired bleeding disorder in 
dogs, causing frank and sometimes fatal 
hemorrhage. The underlying cause of ITP 
is unknown, and there are no predictors 
of disease severity, response, or relapse. 
Despite a general association between 
thrombocytopenia and bleeding, not  
all ITP patients bleed. Consequently, 
veterinarians treat all ITP patients with 
aggressive, non-specific immunosuppres-
sion. High morbidity and mortality result 
not only from uncontrolled bleeding,  
but from treatment side-effects, such  
as fatal opportunistic infections.  
Veterinarians need more specific and more 
individualized ITP treatment suited to 
disease severity and bleeding risk.  
Dr. LeVine’s ITP study aims to develop  
a diagnostic ITP “profile” of immune 
markers that illuminates disease  
pathogenesis. Additionally, since  
a genetic component is indicated by  
a breed predilection in Old English  
sheepdogs and cocker spaniels, the profile 
will include genetic loci associated with 
ITP. This disease characterization will 
allow for novel treatments specifically  
targeting the underlying immune defect. 
The study hopes to identify predictors 
of disease severity, enabling clinicians 
to identify and treat those patients with 
significant bleeding risk.
Dr. LeVine is seeking dogs that are  
thrombocytopenic due to ITP and dogs 
that are thrombocytopenic for other  
reasons (DIC, neoplasia, tick-borne  
disease, etc.) to serve as thrombocytopenic 
controls. Any dog with a platelet count 
less than 50,000/μl may qualify.
To enroll in this study, owners must sign an 
informed consent agreeing to allow a 15 ml 
(1 tablespoon) blood sample and voided 
urine and fecal samples to be collected. 
Go to vetmed.iastate.edu/VetPulse  
to view full list of free tests for dogs 
enrolled in the ITP study.
For more information, or to refer a  
patient, please contact Dr. LeVine at  
515-294-4900 or dnlevine@iastate.edu.
CLINICAL TRIAL: 
Patients Wanted for Clinical Studies in Immune- 
Mediated Hemolytic Anemia and Thrombocytopenia
>> Submit a question at: VetPulse@iastate.edu
Dr. LeVine performs a physical exam on a patient 
enrolled in the study.
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BY Bonnie L. Hay Kraus, DVM, DACVS, DACVAA
Assistant Professor, Anesthesia
Can I use anticholinergic drugs with  
dexmedetomidine in dogs?
The use of anticholinergic drugs with α2- 
agonists has been an area of controversy. 
Some practitioners prefer to administer an anticho-
linergic to reduce the incidence or magnitude of 
bradycardia when administering the less α2-specific 
drug xylazine. However, the newer drug, dexmede-
tomidine, is a more specific α2-agonist. The primary 
mechanism for the bradycardia seen in dogs appears 
to be a baroreceptor reflex due to stimulation of 
peripheral α2b-receptors, rather than a central  
decrease in sympathetic outflow as seen with 
xylazine. Dexmedetomidine causes vasoconstriction, 
a reflex bradycardia and a decrease in cardiac 
output presumably due to the increase in systemic 
vascular resistance. Dogs typically have high normal 
mean arterial blood pressure (MAP) and a significant 
bradycardia which are dose dependent. It is tempting 
to treat this bradycardia with an anticholinergic drug 
such as atropine or glycopyrrolate. 
A recent study evaluated the cardiovascular effects 
of dogs administered dexmedetomidine with and 
without atropine in dogs. Dogs received dexme-
detomidine 10ug/kg IM alone or with atropine 
(0.02mg/kg). Heart rate, cardiac output and blood 
pressure were measured. Dogs receiving dexmede-
tomidine alone had heart rates significantly lower 
than baseline and exhibited sinus arrhythmia and 
second degree atrioventricular block. Atropine- 
treated dogs had heart rates that returned to base-
line; however, MAPs were very high (> 170mmHg) 
and cardiac output was not improved. These dogs 
also developed ventricular premature contractions, 
a sign of decreased myocardial oxygen delivery. 
Recommendation: Do not use an anticholinergic 
to prevent or treat bradycardia associated with 
dexmedetomidine in dogs if MAP is normal to 
high normal. Anticholinergic use may be considered 
in individual patients if it is associated with  
hypotension. Consider reversing with the α2- 
antagonist atipamazole if bradycardia becomes 
severe (<30-35bpm). Sudden arousal may occur 
in anesthetized patients.
Reference: Congdon JM, Marquez M, Niyom S et al. Evaluation of the 
sedative and cardiovascular effects of intramuscular administration of 
dexmedetomidine with and without concurrent atropine administration in 
dogs. J Am Vet Med Assoc. 2011; 239: 81-89.
